Hubei Biocause Pharmaceutical Co., Ltd.

Symboli: 000627.SZ

SHZ

2.3

CNY

Markkinahinta tänään

  • -19.6629

    P/E-suhde

  • 0.1626

    PEG-suhde

  • 11.27B

    MRK Cap

  • 0.05%

    DIV Tuotto

Hubei Biocause Pharmaceutical Co., Ltd. (000627-SZ) Tilinpäätöstiedotteet

Kaaviossa näet oletusarvot Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ). Yrityksen liikevaihto näyttää NaN M keskiarvon, joka on NaN % gowth. Koko jakson keskimääräinen bruttovoitto on NaN M, joka on NaN %. Keskimääräinen bruttovoittosuhde on NaN %. Yrityksen viime vuoden tuloksen nettotuloksen kasvu on NaN %, joka on NaN % % keskimäärin koko yrityksen historian aikana.,

Tase

Hubei Biocause Pharmaceutical Co., Ltd. verotukselliseen kehitykseen sukeltamalla havaitsemme keskimääräisen varallisuuden kasvun. Tämä korko on mielenkiintoisesti , mikä heijastaa sekä yrityksen huippuja että matalimpia lukemia. Neljännesvuosittaisessa vertailussa tämä luku on . Kun tarkastellaan viime vuotta taaksepäin, kokonaisvarojen muutos on NaN. Osakkeenomistajien arvo, jota kuvaa osakepääoman kokonaismäärä, arvostetaan NaN raportointivaluutassa. Tämän näkökohdan vuosittainen muutos on NaN%.

common:word.in-mln

USD
Growth
TTM2023202220212020201920182017201620152014201320122011201020092008200720062005200420032002200120001999199819971996199519941993

balance-sheet.row.cash-and-short-term-investments

02995228391.826157.8
30248.8
15203.5
18317.5
15336.9
10953.2
61.6
58.9
124.3
152.8
74.1
72.9
95.1
306.7
111.3
73.5
26.9
16.8
55.5
73.7
247
104.9
74.6
96
104.9
113.5
13.9
13.9
13.6

balance-sheet.row.short-term-investments

01798.42082.52907.5
3391.6
2211.8
62842.7
4164.8
50767.4
418.6
0
0
0
0
0
0
16.1
3.2
1.3
0
0
0
1.4
0
0
0
0
12
0
13.5
13.5
13.5

balance-sheet.row.net-receivables

00-28453.617772.1
15069.6
10639.8
45548.8
9204.3
7697.9
83.7
140.8
188.6
339.1
391
277
295.6
231
198.2
318.7
428
407.2
455.9
280.7
296.1
28.7
8.7
8
4.1
5.6
3.4
0.2
26

balance-sheet.row.inventory

04131.91050410224.5
10716.2
3671.6
3820.5
569.4
438.5
136.1
140.4
133.9
134.4
150.2
194.2
273.9
259.2
200.4
156.1
135
128.6
125.8
129.8
90.7
70.6
75.6
66.7
16.1
30
18.4
5.3
1.4

balance-sheet.row.other-current-assets

0045535.3-3796
-4291.5
-3729.8
-17868.2
2283.9
645.2
57.7
53.8
-8.1
-98.7
-45.5
-33.6
-29.1
-26.9
0.1
-93.8
-146.6
-130.9
-169.3
0
-105.7
171.7
92.1
73.9
23.9
18.1
23.2
19
-12.8

balance-sheet.row.total-current-assets

050665.955977.650358.4
51743.1
25785
49818.6
27394.5
19734.9
339.2
394
438.7
527.6
569.9
510.5
635.5
770
510
454.5
443.3
421.7
467.9
484.2
528.1
375.9
251.1
244.7
149
167.2
58.9
38.3
28.2

balance-sheet.row.property-plant-equipment-net

01290.6844.1830.3
580.4
567.2
770.9
698.9
587.4
334.7
454.2
619.2
601.7
448.9
527
798.5
612.4
374.3
354.7
336.6
343.3
338.4
322.2
262.9
355.1
376.4
274.9
159.7
111.5
63
32.9
26.5

balance-sheet.row.goodwill

06192.56192.26192.2
6192.2
6186.3
6186.3
6186.3
6186.3
0
0
0
0
0
1.8
1.8
1.8
1.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0283.2299.3269.7
190
109.4
213.4
519.9
549.1
490.4
503.9
363.5
374.7
382.8
410.6
363.6
316.5
261.9
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.goodwill-and-intangible-assets

06475.76491.66461.9
6382.2
6295.7
6399.7
6706.2
6735.4
490.4
503.9
363.5
374.7
382.8
412.3
365.4
318.3
263.7
257.6
179.6
186.8
189.1
184.4
123.5
105
109.3
16.4
16.8
16.3
10.8
3.8
3.9

balance-sheet.row.long-term-investments

0133897.1129743.213020.4
12217.8
12396.1
12983.8
15056.2
8280.1
742
716.8
689.8
543.4
463.3
517.5
330.1
260.4
172.5
100.1
127
127.3
94
100.6
74.4
43.9
22.5
139.1
12
0
13.5
13.5
13.5

balance-sheet.row.tax-assets

026542280.31010.3
976.2
944.2
1189.4
39.5
69.8
69.3
30.5
45.7
17.3
18.7
8.9
9.1
7.6
4.7
-2.7
-127
-127.3
-94
-2.7
0
1.8
1.9
2.3
-12
0
-13.5
-13.5
-13.5

balance-sheet.row.other-non-current-assets

0106952.593262192222.6
167502.9
159285.8
107091.6
90521.3
82469.2
433.6
9.1
0
0
0
0
17.2
10.9
-0.7
3.2
128.4
129.5
95.6
1.7
0.2
4.6
9.4
5
44.3
35.9
1.7
3.1
1.4

balance-sheet.row.total-non-current-assets

0251270232621.1213545.5
187659.6
179488.9
128435.4
113022.2
98141.8
2070.1
1714.5
1718.3
1537.1
1313.7
1465.8
1520.3
1209.6
814.6
712.9
644.6
659.6
623.1
606.2
461
510.4
519.5
437.8
220.8
163.8
75.5
39.8
31.8

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.account-payables

0949206.993.5
35
156.5
83.5
106.1
82.8
74.4
112.8
208.7
84.8
62.6
34.8
37.5
45
67.9
119.6
45.7
51
25.7
26.8
18.6
51.6
29.5
40.1
19
12.5
7.5
3.1
0

balance-sheet.row.short-term-debt

018248.121189.69425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.tax-payables

078.585.1142.5
65.4
223.8
338.4
19.2
53.3
2.1
3.7
-43.3
-48.5
-9.7
0.6
6.9
2.8
29.3
11.2
3.6
2.4
6.6
9.7
32
26.4
15.4
6.2
6.6
15.1
8.8
10.5
2.2

balance-sheet.row.long-term-debt-total

07170.86877.96203.6
2760.3
-69.4
110.5
40.5
360
42
0
0
23
123
123
225
160
30
30
0
0
0
0
0
9
14
14
58.4
56.8
24.4
2.7
5.8

Deferred Revenue Non Current

0179576.7241.8154781.7
147076.1
69.4
10.9
15.3
16
17.6
19.4
0
0
0
0
0
-160
-30
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0463347.4258.5
52
69.4
21424.5
8957.1
2072
8.3
8.8
14.5
12.6
5.9
13.1
20.5
11.8
17.6
21.7
23.7
22.7
19.3
16.8
8.2
12.8
5.3
4.9
0.8
6.4
1.5
0.8
6.9

balance-sheet.row.total-non-current-liabilities

0243840.1229010213369.4
196798.4
162486.6
125753.1
103441.9
93669.4
198.5
41.3
15.8
34.8
134.5
134.5
225
160.2
30
30
0
0
0
0
0
9
16.2
15.2
58.4
56.8
24.4
2.7
5.8

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

071.689.6111.2
69.3
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

0268302.2253995.8226429.3
204814.7
170920.5
152239.5
113711.8
97479.2
625.5
618.8
720.7
527.4
469.5
374.2
581.3
466.8
458.5
443.7
356.7
357.4
372.2
322.4
226.1
291.8
199
189.5
176.6
130.9
82
34.3
18.8

balance-sheet.row.preferred-stock

001085.90
763.7
595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

04940.64940.64940.6
4940.6
4940.6
4940.6
4940.6
4259.2
1353.6
1353.6
1353.6
1353.6
1353.6
1353.6
676.8
676.8
594.8
594.8
594.8
594.8
594.8
594.8
517.2
278.9
232.4
129.1
103.2
103.2
40.5
40.5
40.5

balance-sheet.row.retained-earnings

053106508.56327.4
5909.4
5829
4247.5
3142.4
1922.7
184.6
-37
-171.9
-70.8
-82.7
19
104.6
58.6
106.1
13.1
-31.5
-37.4
-41.7
6.4
27.8
73.4
59.9
36.2
12
32.9
3.4
0
0.8

balance-sheet.row.accumulated-other-comprehensive-income-loss

00-1085.9236.6
-763.7
-595.2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

010339.49962.811048.6
10284.9
10453.5
9804
11254
7619.9
201.5
132.4
214.1
214.7
105.3
172.4
736.8
726.2
113.6
99.1
94.7
93.5
92.8
92.8
143.6
175.4
215.1
312.4
77.9
64
8.5
3.3
0

balance-sheet.row.total-stockholders-equity

020590.12141222553.3
21134.9
21223.1
18992.1
19337
13801.8
1739.7
1449
1395.8
1497.5
1376.2
1545
1518.2
1461.6
814.5
707
658
650.9
645.9
694
688.7
527.7
507.4
477.7
193.2
200.1
52.4
43.9
41.3

balance-sheet.row.total-liabilities-and-stockholders-equity

0301935.9288598.7263904
239402.6
205273.9
178254
140416.7
117876.7
2409.2
2108.5
2157
2064.7
1883.6
1976.3
2155.7
1979.5
1324.5
1167.4
1087.9
1081.3
1091
1090.4
989.1
886.3
770.7
682.5
369.8
331
134.4
78.2
60.1

balance-sheet.row.minority-interest

013043.71319114921.3
13453
13130.4
7022.5
7367.8
6595.7
44
40.7
40.4
39.9
37.9
57
56.3
51.2
51.6
16.7
73.2
73
72.9
74.1
74.3
66.8
64.2
15.3
0
0
0
0
0

balance-sheet.row.total-equity

033633.834602.937474.7
34587.9
34353.5
26014.5
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

0135695.6131825.7116261.7
119224.9
120538.2
75826.6
61072.9
59047.4
1160.6
716.8
689.8
543.4
463.3
517.5
330.1
244.3
169.3
98.7
127
127.3
94
99.2
74.4
43.9
22.5
139.1
24
0
27
27
27

balance-sheet.row.total-debt

025418.928067.59425.8
4583.8
6179.8
4640
7732.3
1414
303.5
428.9
484.6
327.8
253.2
142.8
274.8
192.7
279.4
231.9
252.4
251.4
284.4
249.4
134.5
154.4
96.4
54.9
7.7
14.9
8.1
3.3
6

balance-sheet.row.net-debt

0-2734.71758.2-13824.5
-22273.3
-6811.9
-13677.5
-3439.9
-9539.2
241.9
370
360.3
175
179.1
69.9
179.7
-97.9
171.4
159.7
225.5
234.6
228.9
177.1
-112.5
49.6
21.7
-41.1
-85.2
-98.7
7.7
2.9
5.9

Kassavirtalaskelma

Hubei Biocause Pharmaceutical Co., Ltd. taloudessa on tapahtunut huomattava muutos vapaan kassavirran määrässä viimeisen ajanjakson aikana, ja se on muuttunut NaN suuntaan. Yhtiö on hiljattain laajentanut osakepääomaansa laskemalla liikkeeseen NaN, mikä merkitsee NaN eroa edelliseen vuoteen verrattuna. Yhtiön investointitoiminnasta aiheutui nettokassan käyttöä, joka oli NaN raportointivaluutassa. Tämä on NaN siirtymä edellisestä vuodesta. Samana ajanjaksona yhtiö kirjasi NaN, NaN ja NaN, jotka ovat merkittäviä yrityksen investointi-ja takaisinmaksustrategioiden ymmärtämisen kannalta. Yhtiön rahoitustoiminta johti siihen, että nettokassan käyttö oli NaN, ja ero edellisvuoteen oli {{year_over_year_net_cash_from_financing_activities_change_percentage}}. Lisäksi yhtiö osoitti NaN osingonjakoon osakkeenomistajilleen. Samaan aikaan se toteutti myös muita rahoitusmanöövereitä, joihin viitataan nimellä {{other-financing-activities}}, jotka myös vaikuttivat merkittävästi sen kassavirtaan kyseisenä ajanjaksona. Nämä osatekijät muodostavat yhdessä kattavan kuvan yrityksen taloudellisesta tilanteesta ja strategisesta lähestymistavasta kassavirran hallintaan.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998

cash-flows.row.net-income

0510.6880.21117.9
2918.6
2377.3
2678.3
3108.8
250.5
84.1
-100.4
13.8
-107.2
29.1
55.3
17.1
101.6
53.1
8.1
4.9
-49
7.8
46.7
40.3
35.4
30.5

cash-flows.row.depreciation-and-amortization

0147.3133.963.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

016073.111933.530709.3
35361
-26789.8
5245.9
-6232.5
23.9
-78.9
116.7
78
51.7
149.3
-122.8
-96.1
27.3
51.8
-13.7
15
-22.3
-131.2
-41.5
-83.5
-23.6
-52.1

cash-flows.row.account-receivables

01642.4-609.1-279.5
1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

0-279.6471.1-188.3
177.6
120.5
-130.9
-302.4
1.7
-6.5
0.5
15.8
12.3
79.7
-14.7
-58.7
-44.4
-21
-6.4
-1.8
4
-37.2
-20.1
4.9
8.9
-29

cash-flows.row.account-payables

0-1642.4609.1279.5
-1548.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

016352.611462.530897.6
35183.5
-26910.3
5376.7
-5930.1
22.2
-72.4
116.2
62.2
39.5
69.6
-108.1
-37.3
71.6
72.9
-7.3
16.8
-26.3
-94
-21.4
-88.4
-32.5
-23.1

cash-flows.row.other-non-cash-items

0-9206.7-8775.1-10469.8
-9759.2
38269.9
-7615.5
642
-385.9
-200
45.4
-50.4
59.5
-20.2
-5.3
24.9
-52.3
-12.4
16.7
0.3
11.2
16.5
3.2
10
10
3.4

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.acquisitions-net

0171.8-3440.5
258.8
334.3
1.4
3.5
3.2
103.1
162.9
131
44.3
0
263.4
361.8
65.9
130.1
0
28.3
21.8
146.9
0.2
10.7
0
10.8

cash-flows.row.purchases-of-investments

0-97626.8-109755-71494.6
-123082.8
-77372.7
-139091.6
-115403.5
-6.2
-230
-146.7
-60
-40
-120.1
-40
-189
-60
-55.6
-0.8
-39
-165.8
-184.7
-24.8
-20.2
0
-31.5

cash-flows.row.sales-maturities-of-investments

084126.194717.767783.5
88942.6
68035
129051.5
104526.6
182.1
464.4
89
130
170
0
17.8
92.7
43.2
26.7
0
15.6
175.7
129.6
1.1
12.2
29.9
12

cash-flows.row.other-investing-activites

0-1996.2-62.2-222.2
-445.9
102.8
-47.8
17138.3
7.1
5.3
-143.8
-128.5
-149.4
207.6
-261.7
-361.7
-64.8
-130.1
0
-25.5
-21.5
-146.1
62
-6.3
0.5
-10.8

cash-flows.row.net-cash-used-for-investing-activites

0-15615-15384.8-7682.2
-35044.3
-9175.3
-10865.4
2586.6
145.4
157.2
-182.4
-56
-124.4
-5.6
-282.2
-458
-80.4
-159
-25.3
-46.2
-11.3
-200.6
7
-9.9
-68.8
-30.3

cash-flows.row.debt-repayment

0-11763.8-7701.9-854.1
-102.8
-288
-790
-447.5
-464.9
-573.5
-463.3
-294.8
-223.3
-594.8
-279.7
-413.2
-231.9
-255.8
-240.6
-235.4
-329.9
-345.9
-178.9
-59.8
-67.9
-17.2

cash-flows.row.common-stock-issued

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-699.4-381.3-634
-242.1
-311.6
-148
-117.1
-24.5
-30.6
-30.4
-28.7
-21.6
-37.3
-20
-52.4
-17.8
-12.3
-14.3
-15.5
-15
-16.1
-22.7
-15.1
-6.2
-58.7

cash-flows.row.other-financing-activites

02354115703.91660.6
1470.2
1940.4
11597.1
11190.3
407
515.3
484.6
364.4
303.7
390.8
406.8
1119.6
247.4
344.2
241.6
202.4
364.9
457.5
299.4
119.6
74.8
114.5

cash-flows.row.net-cash-used-provided-by-financing-activities

011077.87620.6172.6
1125.3
1340.8
10659.2
10625.7
-82.4
-88.8
-9.1
40.9
58.8
-241.3
107.2
654.1
-2.3
76.2
-13.3
-48.6
20
95.5
97.8
44.7
0.6
38.6

cash-flows.row.effect-of-forex-changes-on-cash

072-15.2-33.9
-1.4
1.6
-2.1
3.8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-0.1
0

cash-flows.row.net-change-in-cash

03059-3606.913877.6
-5320.8
7148.4
223.2
10873.7
16.2
-52.8
-61.1
78.7
1.3
-22.2
-195.5
182.6
35.8
45.3
10
-38.7
-16.8
-174.7
142.2
30.2
-21.4
3.1

cash-flows.row.cash-at-end-of-period

026309.323250.326857.1
12979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96

cash-flows.row.cash-at-beginning-of-period

023250.326857.112979.5
18300.4
11152
10928.8
55.1
38.9
91.8
152.8
74.1
72.9
95.1
290.6
108
72.2
26.9
16.8
55.5
72.3
247
104.9
74.6
96
92.9

cash-flows.row.operating-cash-flow

07524.24172.621421.1
28599.6
14981.3
431.6
-2342.3
-46.7
-121.3
130.5
93.8
66.9
224.6
-20.5
-13.5
118.6
128.2
48.7
56.1
-25.9
-69.6
37.3
-4.6
46.9
-5.2

cash-flows.row.capital-expenditure

0-135.1-287.1-308.4
-717.1
-274.7
-778.9
-3678.3
-40.8
-185.5
-143.8
-128.5
-149.4
-93.1
-261.7
-361.7
-64.8
-130.1
-24.5
-25.5
-21.5
-146.1
-31.5
-6.3
-99.2
-10.8

cash-flows.row.free-cash-flow

07389.13885.521112.7
27882.5
14706.7
-347.4
-6020.6
-87.5
-306.8
-13.3
-34.7
-82.4
131.5
-282.2
-375.2
53.8
-1.9
24.1
30.5
-47.4
-215.8
5.8
-10.9
-52.3
-16

Tuloslaskelmarivi

Hubei Biocause Pharmaceutical Co., Ltd. liikevaihto muuttui NaN% edelliseen kauteen verrattuna. 000627.SZ:n bruttovoitto ilmoitetaan NaN. Yrityksen toimintakulut ovat NaN, ja niissä on tapahtunut NaN%:n muutos edelliseen vuoteen verrattuna. Poistojen ja arvonalentumisten kulut ovat NaN, mikä on NaN% muutos edellisestä tilikaudesta. Toimintakulujen ilmoitetaan olevan NaN, mikä osoittaa NaN%:n muutoksen edellisvuoteen verrattuna. Myynti- ja markkinointikulut ovat NaN, mikä on NaN% muutos edelliseen vuoteen verrattuna. Viimeisimpiin lukuihin perustuva käyttökate on NaN, mikä vastaa NaN%:n kasvua edellisvuoteen verrattuna. Liikevoitto on NaN, joka osoittaa NaN%:n muutosta edelliseen vuoteen verrattuna. Nettotuloksen muutos on NaN%. Viime vuoden nettotulos oli NaN.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995

income-statement-row.row.total-revenue

049725.849615.749583.2
43576
50192.1
30950.8
53405.6
16995.5
541.1
806.4
968
779.7
1133.8
1261.2
964.6
909.3
835.8
560.8
518.7
463
422.7
348.6
356
322
255.9
192.3
237.5
143.7
83.3

income-statement-row.row.cost-of-revenue

09829.68458.67311.6
3225.1
8172.6
2866.9
4036.6
1788.5
518
829.8
977.5
753.2
1111.8
1185.8
866.2
835.1
726.1
475.6
451.1
410.6
380.8
268.7
261.2
240.2
193
155.3
176.4
98.2
53.9

income-statement-row.row.gross-profit

039896.241157.142271.6
40350.8
42019.5
28083.9
49368.9
15207
23.1
-23.4
-9.6
26.5
22
75.3
98.4
74.2
109.7
85.1
67.7
52.5
41.8
79.9
94.9
81.8
62.8
37
61.2
45.6
29.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.operating-expenses

0-48509.610159.510437.9
36774.7
30668.5
2614.7
26761
6911.4
79.6
70.9
73.6
63.9
80.2
67.9
52.8
59
55.4
45.9
49.3
50.8
83.4
57
45
36.6
36.2
13
10
10.3
6.8

income-statement-row.row.cost-and-expenses

0-51566.718618.117749.5
39999.8
38841.1
5481.6
30797.6
8699.9
597.6
900.7
1051.1
817.1
1192
1253.7
919
894.1
781.4
521.5
500.4
461.3
464.2
325.6
306.1
276.7
229.2
168.3
186.3
108.5
60.7

income-statement-row.row.interest-income

0000
0
0
0
16.1
0
2.3
2.6
1.5
2.2
3.7
1.8
2.7
14.7
4.2
3.9
0.5
3.2
0.2
1.7
5.2
1.5
0
0
0
0
0

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0-48509.69825.59896.8
36146.5
30062.1
-24280.3
-23688.3
-6190.4
3.1
8.3
13.2
1.5
0.3
9.8
6
5
6
10.3
4.7
9.5
1.5
2.6
8.3
7.3
20.6
11.9
5.6
6.6
2

income-statement-row.row.total-operating-expenses

0-1868-30964.1-32573.9
-2432.1
-8419.3
-18306.3
-4428.3
-1585.5
390.9
203.2
-45.4
52.4
-58.5
23.6
13.6
-7.9
58.1
13.2
-14.4
0.5
-9.5
-9.1
-0.2
-3.1
6.1
12.8
6.6
10.1
6.2

income-statement-row.row.interest-expense

0031200.6423.8
170.5
101.3
0
0
0
24.5
30.6
30.4
28.7
21.6
25.8
23.3
32.1
21
16.1
14.3
13.9
15.5
10.7
8.5
8.3
-0.4
-0.6
0.3
1.4
0.3

income-statement-row.row.depreciation-and-amortization

01840.9147.3133.9
63.7
79.2
1123.9
122.9
139.3
64.8
73.5
68.8
52.4
62.9
66.5
52.3
40.5
42
35.6
37.6
35.9
34.2
37.3
28.9
28.6
25.1
13.1
-11.9
-13.4
-8.3

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

01216.331188.832917
3881.5
12052.8
2653.6
2727.4
3424.8
332.2
101.1
-141.1
14.9
-113.7
22.2
53.2
2.3
106.4
53.1
8.2
-1.7
-45.1
15.8
57.5
48.3
41.8
30.7
63.1
48.6
30.8

income-statement-row.row.income-before-tax

0-1868224.8343.1
1449.5
3633.4
2636.4
2724.3
3432.6
334.4
109
-128.6
15
-116.7
31.1
59.2
7.3
112.4
57.9
8.4
5
-47.3
16.2
57.7
48.9
47.6
39.7
63.3
50.3
30.8

income-statement-row.row.income-tax-expense

0-1216.3-285.8-537.1
331.6
714.9
259.1
46
323.7
83.9
24.8
-28.1
1.2
-9.5
2
3.9
-0.1
20.5
4.8
0.3
0.1
1.7
8.3
11
8.5
12.2
9.2
8.5
13.4
8

income-statement-row.row.net-income

0-651.8510.6880.2
1117.9
2918.6
1326.5
1326.2
1778.7
247.3
83.8
-101
11.8
-101.7
28.3
55.8
-23.8
89.7
48.4
7.1
5.1
-48.1
5.3
37.2
34.2
31.3
30.2
54.8
36.9
22.8

Usein kysytty kysymys

Mikä on Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) taseen loppusumma?

Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) kokonaisvarat ovat 301935930342.000.

Mikä on yrityksen vuotuinen liikevaihto?

Vuotuinen liikevaihto on N/A.

Mikä on yrityksen voittomarginaali?

Yrityksen voittomarginaali on 0.698.

Mikä on yrityksen vapaa kassavirta?

Vapaa kassavirta on -2.454.

Mikä on yrityksen nettovoittomarginaali?

Nettovoittomarginaali on -0.007.

Mikä on yrityksen kokonaistulot?

Kokonaisliikevaihto on 0.006.

Mikä on Hubei Biocause Pharmaceutical Co., Ltd. (000627.SZ) nettovoitto (nettotulos)?

Nettovoitto (nettotulos) on -651784800.000.

Mikä on yrityksen kokonaisvelka?

Kokonaisvelka on 25418877126.000.

Mikä on yrityksen toimintakulujen määrä?

Toimintakulut ovat -48509569700.000.

Mikä on yrityksen kassan määrä?

Yrityksen kassavarat ovat 0.000.